Table 1 Baseline clinical characteristics of patients with or without thrombotic events in AAV patients
From: Renal damage and old age: risk factors for thrombosis in patients with ANCA-associated vasculitis
Variables | Total (n = 1203) | Thrombosis (n = 136) | Non-thrombosis (n = 1067) | P value |
|---|---|---|---|---|
Age | 55 ± 17 | 60 ± 14 | 54 ± 17 | < 0.001 |
Gender (Male) | 625 (52.0%) | 71 (52.2%) | 554 (51.9%) | 0.95 |
Smoking | 382 (31.8%) | 51 (37.5%) | 331 (31.0%) | 0.003 |
System involvement | Â | Â | Â | |
 Kidney | 785 (65.3%) | 91 (66.9%) | 694 (65.0%) | 0.666 |
 Lung | 660 (54.9%) | 95 (69.9%) | 565 (53%) | < 0.001 |
 Neurological | 216 (18.0%) | 41 (30.1%) | 175 (16.4%) | < 0.001 |
 ENT | 322 (26.8%) | 41 (30.1%) | 281 (26.3%) | 0.344 |
Commodities | Â | Â | Â | |
 Hypertension | 527 (43.8%) | 72 (52.9%) | 455 (42.6%) | 0.023 |
 Diabetes | 341 (28.4%) | 32 (23.5%) | 309 (29%) | 0.186 |
 CHD | 49 (4.1%) | 7 (5.1%) | 42 (3.9%) | 0.501 |
 CKD | 197 (16.4%) | 31 (22.8%) | 166 (15.6%) | 0.032 |
 ESRD | 151 (12.6%) | 32 (23.5%) | 119 (11.2%) | < 0.001 |
 COPD | 40 (3.3%) | 6 (4.4%) | 34 (3.2%) | 0.453 |
 Stroke | 93 (7.7%) | 16 (11.8%) | 77 (7.2%) | 0.061 |
 Malignancy | 74 (6.15%) | 8 (5.88%) | 66 (6.19%) | 0.890 |
AAV classification | Â | Â | 0.003 | |
 MPA | 602 (50.0%) | 63 (46.3%) | 539 (50.5%) |  |
 GPA | 357 (29.7%) | 31 (22.8%) | 326 (30.6%) |  |
 EGPA | 190 (15.8%) | 37 (27.2%) | 153 (14.3%) |  |
ANCA | Â | Â | Â | Â |
 p-ANCA | 493(41.0%) | 47(34.6%) | 446(41.8%) | 0.106 |
 c-ANCA | 217(18.0%) | 24(17.6%) | 193(18.1%) | 0.9 |
 MPO | 197(16.4%) | 21(15.4%) | 176(16.5%) | 0.754 |
 PR3 | 464(38.6%) | 50(36.8%) | 414(38.8%) | 0.646 |
Hypoalbuminemia | 301 (25.8%) | 44 (33.3%) | 257 (24.8%) | 0.035 |
EOS (×10^9/L) | 0.20 (0.02-1.00) | 0.14 (0.01–0.59) | 0.20 (0.02-1.00) | 0.113 |
Scr (µmol/L) |  |  | < 0.001 | |
 < 124 | 720 (61.7%) | 68 (51.5%) | 652 (63.1%) |  |
 125–249 | 187 (16.0%) | 20 (15.2%) | 167 (16.2%) |  |
 249–499 | 160 (13.7%) | 20 (15.2%) | 140 (13.5%) |  |
 > 500 | 99 (8.5%) | 24 (18.2%) | 75 (7.3%) |  |
D-dimer (mg/L) | 1.4 (0.6–3.5) | 3.0 (1.3–17.2) | 1.2 (0.5–3.1) | < 0.001 |
Elevated ESR | 766 (72.8%) | 77 (66.4%) | 689 (73.6%) | 0.099 |
Elevated CRP | 633 (57.7%) | 76 (60.8%) | 557 (57.2%) | 0.449 |
Decreased C3 | 110 (13.1%) | 16 (16.7%) | 94 (12.7%) | 0.273 |
Decreased C4 | 60 (7.1%) | 10 (10.4%) | 50 (6.7%) | 0.176 |
Complications | Â | Â | Â | |
 Infection | 323 (26.9%) | 49 (36%) | 274 (25.7%) | 0.01 |
 Anemia | 380 (31.6%) | 56 (41.2%) | 324 (30.4%) | 0.011 |
Treatment | Â | Â | Â | Â |
 GC po. | 1162 (96.6%) | 133(97.8%) | 1029(96.4%) | 0.412 |
 GC pulse. | 298 (24.8%) | 38 (27.9%) | 260 (24.4%) | 0.363 |
 CTX | 868 (72.2%) | 103 (75.7%) | 765 (71.7%) | 0.322 |
 RTX | 75 (6.2%) | 6 (4.4%) | 69 (6.5%) | 0.351 |
 PE | 39 (3.2%) | 7 (5.1%) | 32 (3%) | 0.183 |
 Dialysis | 113 (9.39) | 30 (22.06) | 83 (7.78) | < 0.001 |
Death | 63 (5.2%) | 7 (5.2%) | 56 (5.3%) | 0.96 |
Length of stay (days) | 23.3 ± 13.8 | 29.6 ± 17.1 | 22.6 ± 13.2 | < 0.001 |